Results 131 to 140 of about 848 (155)
An Update on Recent Clinical Trial Data in Bloodstream Infection. [PDF]
Antibiotics (Basel)Stewart AG +6 more
europepmc +1 more source
Analysis of the isoprenoid part of sterol biosynthesis in fungal and mammalian matrices [PDF]
Liebl, Maximilian
core
Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus [PDF]
Antimicrobial Agents and Chemotherapy, 2020 Mucormycosis is a life-threatening infection with high mortality that occurs predominantly in immunocompromised patients. Manogepix (MGX) is a novel antifungal that targets Gwt1, a protein involved in an early step in the conserved glycosylphosphotidyl inositol (GPI) posttranslational modification pathway of surface proteins in eukaryotic cells ...
Teclegiorgis Gebremariam +2 more
exaly +13 more sources
The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections [PDF]
Antimicrobial Agents and Chemotherapy, 2022 Invasive pulmonary aspergillosis (IPA), invasive mucormycosis (IM), and invasive fusariosis (IF) are associated with high mortality and morbidity. Fosmanogepix (FMGX) is a first-in-class antifungal in clinical development with demonstrated broad-spectrum activity in animal models of infections.
Karen Joy Shaw, Ashraf S Ibrahim
exaly +10 more sources
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]
Drugs, 2021 The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and ...
Martin Hoenigl +2 more
exaly +5 more sources
Antimicrobial Agents and Chemotherapy, 2023 Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX, interferes with cell wall synthesis by targeting fungal glycosylphosphatidylinositol-anchored cell wall ...
Abhijeet Jakate, Margaret Tawadrous
exaly +3 more sources